Literature DB >> 25956676

Liver enzyme abnormalities in taking traditional herbal medicine in Korea: A retrospective large sample cohort study of musculoskeletal disorder patients.

Jinho Lee1, Joon-Shik Shin1, Me-Riong Kim1, Jang-Hoon Byun1, Seung-Yeol Lee1, Ye-Sle Shin1, Hyejin Kim1, Ki Byung Park1, Byung-Cheul Shin2, Myeong Soo Lee3, In-Hyuk Ha4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: The objective of this study is to report the incidence of liver injury from herbal medicine in musculoskeletal disease patients as large-scale studies are scarce. Considering that herbal medicine is frequently used in patients irrespective of liver function in Korea, we investigated the prevalence of liver injury by liver function test results in musculoskeletal disease patients.
MATERIALS AND METHODS: Of 32675 inpatients taking herbal medicine at 7 locations of a Korean medicine hospital between 2005 and 2013, we screened for liver injury in 6894 patients with liver function tests (LFTs) at admission and discharge. LFTs included t-bilirubin, AST, ALT, and ALP. Liver injury at discharge was assessed by LFT result classifications at admission (liver injury, liver function abnormality, and normal liver function). In analyses for risk factors of liver injury at discharge, we adjusted for age, sex, length of stay, conventional medicine intake, HBs antigen/antibody, and liver function at admission.
RESULTS: A total 354 patients (prevalence 5.1%) had liver injury at admission, and 217 (3.1%) at discharge. Of the 354 patients with liver injury at admission, only 9 showed a clinically significant increase after herbal medicine intake, and 225 returned to within normal range or showed significant liver function recovery. Out of 4769 patients with normal liver function at admission, 27 (0.6%) had liver injury at discharge. In multivariate analyses for risk factors, younger age, liver function abnormality at admission, and HBs antigen positive were associated with injury at discharge.
CONCLUSIONS: The prevalence of liver injury in patients with normal liver function taking herbal medicine for musculoskeletal disease was low, and herbal medicine did not exacerbate liver injury in most patients with injury prior to intake.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Complementary therapies; Drug-induced liver injury; Herbal medicine; Liver function tests; Risk factors

Mesh:

Year:  2015        PMID: 25956676     DOI: 10.1016/j.jep.2015.04.048

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  4 in total

1.  Long term follow-up of cervical intervertebral disc herniation inpatients treated with integrated complementary and alternative medicine: a prospective case series observational study.

Authors:  Sang Hyun Baek; Jae Woo Oh; Joon-Shik Shin; Jinho Lee; Yoon Jae Lee; Me-riong Kim; Yong-jun Ahn; Areum Choi; Ki Byung Park; Byung-Cheul Shin; Myeong Soo Lee; In-Hyuk Ha
Journal:  BMC Complement Altern Med       Date:  2016-02-04       Impact factor: 3.659

2.  Influence of Boiling Duration of GCSB-5 on Index Compound Content and Antioxidative and Anti-inflammatory Activity.

Authors:  In-Hee Lee; Hwa-Jin Chung; Joon-Shik Shin; In-Hyuk Ha; Me-Riong Kim; Wonil Koh; Jinho Lee
Journal:  Pharmacogn Mag       Date:  2017-07-19       Impact factor: 1.085

3.  Effectiveness and Safety of the Korean Medicine Senior Health Promotion Program Using Herbal Medicine and Acupuncture for Mild Cognitive Impairment: A Retrospective Study of 500 Patients in Seoul, Korea.

Authors:  Hyo-Weon Suh; Jae-Hyun Seol; Eun-Joo Bae; Hui-Yong Kwak; Sunggyu Hong; Yong-Sin Park; Jae Hwan Lim; Sun-Yong Chung
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-06       Impact factor: 2.629

4.  Prevention and management of adverse events following COVID-19 vaccination using traditional Korean medicine: An online survey of public health doctors.

Authors:  Byungsoo Kang; Hongmin Chu; Bo-Young Youn; Jungtae Leem
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.